No products in the cart.
In human prostate cancer, the ERG oncogene is frequently overexpressed due to chromosomal translocations involving ERG and regulatory sequences of the TMPRSS2 or other androgen responsive genes. Recently, a mouse monoclonal anti-ERG antibody was developed with an unprecedented 99.9% specificity for detecting prostatic adenocarcinoma. The report shows strong correlation between the expression of the ERG protein and the presence of TMPRSS2:ERG rearrangement and a remarkable concordance (96.5%) of ERG positive prostatic intraepithelial neoplasia (PIN) and ERG positive carcinoma in prostatectomy specimens.
Therefore, as a hallmark of the TMPRSS2:ERG chromosomal translocation, ERG expression offers a rare, but definitive marker of adenocarcinoma of prostatic origin, and unique opportunities to indicate oncogenic activations in PIN, to stratify prostate cancer patients for ERG oncogene status and to monitor treatment efficacy.
AMACR (P504S) protein is expressed in prostatic adenocarcinoma, but not in benign prostatic tissue. It has also been found to be expressed in some premalignant lesions of the prostate: high-grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia. AMACR can be used as a positive marker for prostate cancer and may be useful to confirm small foci of prostate carcinoma in needle biopsies. AMACR stains the majority of prostate cancer; however, AMACR has been shown to stain many other types of carcinomas such as hepatoma, breast carcinoma, pancreatic and islet tumors.
Note: ERG [9FY] was developed by the Center for Prostate Disease Research in association with the Henry M. Jackson Foundation, Rockville, Maryland. U.S. Patent 8,765,916 and patents pending
Mouse Monoclonal, Rabbit Monoclonal
9FY + 13H4
ERG and AMACR
ERG (Nuclear): Brown with MACH 2 Double Stain 2 or Red with MACH 2 Double Stain 1. AMACR (Cytoplasmic): Red with MACH 2 Double Stain 2 or brown with MACH 2 Double Stain 1.
ERG positive prostate cancer with normal and/or PIN glands
1. Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y-D, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey
M, Moul WJ, Srivastava S. Frequent overexpression of ETS related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847-3852 (2005).
2. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8, 497-511 (2008).
3. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA. ERG oncoprotein expression in prostate cancer: clonal progression of ERG positive tumor cells and potential for ERG based stratification. Prostate Cancer and ProstaticDiseases 13, 228-237 (2010).
4. Mohamed AA, Tan S-H, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, Sesterhenn IA, Dobi A, Srivastava S, Sreenath LT. Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody. Journal of Cancer 1, 197-208 (2010).
5. Miettinen M, Wang Z-F, Paetau A, Tan S-H, Dobi A, Srivastava S, Sesterhenn IA.:ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. American Journal of Surgical Pathology 35, 432-441 (2011).
6. Mohamed AA, Tan S-H, Sun C, Shaheduzzaman S, Hu Y, Petrovics G, Chen Y, Sesterhenn IA, Li H, Sreenath T, McLeod DG, Dobi A, Srivastava S. ERG oncogene modulates prostaglandin signaling in prostate cancer cells, Cancer Biology and Therapy 11, 410-417 (2011).
7. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 22, 88-104 (2005).
8. Trpkov K, Bartczak-McKay J, Yilmaz A. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. Am J Clin Pathol 132, 211-220 (2009).
9. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
10. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.